Benzinga | Apr 15, 2021 08:15AM EDT

Brickell Biotech Highlights Publication Of Its HDSM-Ax Patient Reported Outcome Scale Validation Results In Journal Of Drugs In Dermatology

Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced that results from a Phase 2b study evaluating the use of Hyperhidrosis Disease Severity Measure-Axillary(c) (HDSM-Ax), Brickell's proprietary patient reported outcome (PRO) scale, to measure primary axillary hyperhidrosis (AHH) severity were published in the peer-reviewed Journal of Drugs in Dermatology. The article, entitled "Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax): Evaluation of Measurement Performance," can be accessed online here.